|
|
Nanoco Group PLC - Comparative Business Analysis Snapshot
Business Description
Nanoco Group PLC Formerly known as Evolutec Group PLC. The Group's principal activity is providing research and development of biopharmaceutical products. It develops drugs for allergy, inflammation and autoimmune disease. Products include rEV131, rEV576, rEV598 and anti-tick vaccine. The Group operates in The United Kingdom, Rest of Europe and North America.
Competitor Analysis
This analysis compares Nanoco Group PLC with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
